Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2007-05-01
2007-05-01
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S141100
Reexamination Certificate
active
10772437
ABSTRACT:
A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.
REFERENCES:
patent: 5733748 (1998-03-01), Yu et al.
patent: 6309857 (2001-10-01), Pauli et al.
patent: WO 96/39419 (1996-12-01), None
Agnel et al. Identification of three novel members of the calcium-dependent chloride channel (CaCC) family predominantly expressed in the digestive tract and trachea. FEDS Letters 455: 295-301 (1999).
Gruber et al. Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of CA2+-activated Cl- channel proteins, Genomics 54(2):200-14 (1998).
Chu et al., Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation, Cell. Immunol. 145:223-239 (1992).
Cunningham et al., SA, Cloning of an epithelial chloride channel from bovine trachea, J. Biol. Chem. 270(52):31016-26 (1995).
Dong et al. , Il-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice, Eur. J. Immunol. (7):2130-9 (1999).
Doucet et al., Interleukin (IL) 4 and IL-13 act on human lung fibroblasts. Implication in asthma, J. Clin. Invest. 101(10):2129-39 (1998).
Doull et al., Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness, Am. J. Respir. Crit. Care Med. 153(4 Pt 1):1280-4 (1996).
Dugas et al, Interleukin-9 potentiates the interleukin-4-induced immunoglobulin (IgG, IgM and IgE) production by normal human B lymphocytes, Eur. J. Immunol. 23:1687-1692 (1993).
Eklund et al., Induction by IL-9 and suppression by IL-3 and IL-4 of the levels of chromosome 14-derived transcripts that encode late-expressed mouse mast cell proteases, J. Immunol. 151:4266-4273 (1993).
Elble RC, Widom J, Gruber AD, Abdel-Ghany M, Levine R, Goodwin A, Cheng HC, Pauli BU. Cloning and characterization of lung-endothelial cell adhesion molecule-1 suggest it is an endothelial chloride channel. J Biol Chem Oct. 31, 1997;272(44):27853-61.
Eng et al., Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis,Pediatr. Pulmonol. 21:77-83 (1996).
Kreitman et al., Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity, Biochemistry 33(38):11637-44 (1994).
Levitt et al., Emerging therapeutic targets in asthma: a role for interleukin-9, Emerg. Thera. Targets, 3:1-11 (1999).
McLane et al., Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice, Am. J. Respir. Cell Mol. Biol. 19(5):713-20 (1998).
Nicolaides et al., Interleukin 9: a candidate gene for asthma, Proc. Natl. Acad. Sci. USA, 94(24):13175-80 (1997).
Petit-Frere et al., Interleukin-9 potentiates the interleukin-4-induced IgE and IgG1 release from murine B lymphocytes, Immunology ,79:146-151 (1993).
Temann et al., Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness, J. Exp. Med. 188(7):1307-20 (1998).
Zav'yalov et al., Nonapeptide corresponding to the sequence 27-35 of the mature human IL-2 efficiently competes with RiL-2 for binding to thymocyte receptors [corrected], Immunol Lett. 31(3):285-8 (1992).
International Search Report dated Jul. 9, 1999 from International Application No. PCT/US99/04703, 2 pages.
Agnel et al. (1999) Identification of three novel members of the calcium-dependent chloride channel (CaCC) family predominantly expressed in the digestive tract and trachea, FEBS Letters 455:295-301.
Dong Qu
Holroyd Kenneth J.
Levitt Roy C.
Louahed Jamila
Maloy W. Lee
Genaera Corporation
Mertz Prema
Morgan & Lewis & Bockius, LLP
LandOfFree
Methods for treating ICACC protein associated diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating ICACC protein associated diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating ICACC protein associated diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3775962